The ambition of the MRGM is to decipher the molecular mechanisms laying at the root of the pathophysiology of rare diseases and make our findings worth for patients.

MRGM Main Pipeline

Research at MRGM (INSERM U1211) lays on 2 branches:

  • In the Genetic anomalies of Development axe, we are identifying and characterizing candidate genes that are linked to various rare diseases including albinism, Oculo-Auriculo-Vertebral Spectrum (OAVS), Rubinstein-Taybi syndrome, and pathologies associated to RAS dysfunction.

  • In the innate errors of mitochondrial metabolism axe, we are investigating how mitochondrial bioenergetics and dynamics govern fundamental cellular functions involved in rare diseases, cancer and immune responses. One part is more physiopathological: genetic and biochemical alterations of altered metabolic pathways. The other part is more fundamental: analysis of the biochemical pathways of energy and lipid metabolism.

The MRGM closely intertwines with patient associations and the University of Bordeaux to anchor in the society. Together with the Genetic Department of the Public Hospital of Bordeaux, the MRGM is part of the French Centers of References for Developmental Anomalies (SOOR), Neurogenetic Diseases (NEUROGENE), and Mitochondrial Diseases (CARAMMEL), thereby contributing in improving public health system and patient care.

Our aim is to improve diagnosis, reveal new targets, and develop new drugs for the treatment of rare diseases.

We are on Twitter and LinkedIn





IMG_4251 NewsClick here